Theriva Biologics Builds Momentum with New VIRAGE Phase 2b VCN-01 Data Presentation Set for AACR 2026

Tumor Response and Biomarker Data Reaffirm VCN-01’s Potential in Metastatic Pancreatic Cancer

Theriva Biologics (NYSE:TOVX) announced it will present additional data from its VIRAGE Phase 2b clinical trial of VCN-01 at the American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego. The company’s progress is drawing attention as new tumor response, biomarker, and subgroup analyses suggest VCN-01 may offer improved outcomes for metastatic pancreatic cancer patients—especially those with liver metastases—a group often facing limited options and poor prognosis.

Upcoming Data Presentation Signals a Step Toward Advanced Pancreatic Care

The latest results, led by Dr. Manuel Hidalgo of NYU Langone Health Perlmutter Cancer Center, will be presented during a poster session on April 20, 2026. According to Theriva, these findings support an immune-mediated mechanism for VCN-01 and indicate that patients treated with the therapy in combination with gemcitabine/nab-paclitaxel chemotherapy may experience longer response durations and potential survival benefits compared with standard treatment alone.

Theriva Pushes Forward with Phase 3 Plans After FDA and EMA Alignment

The new analyses support Theriva’s confidence in its approach, with CEO Steven A. Shallcross noting that, “alignment with both the FDA and the EMA on a proposed pivotal Phase 3 clinical trial to evaluate multiple doses of VCN-01 plus gemcitabine/nab-paclitaxel in first-line metastatic PDAC patients,” has been achieved. The company also plans a smaller study to assess if more frequent and extended dosing could further improve patient outcomes.

Therapeutic Innovation Targets Major Unmet Needs in PDAC

Pancreatic ductal adenocarcinoma (PDAC) represents over 90% of all pancreatic cancers and is usually diagnosed at an advanced stage, leaving most patients ineligible for surgery. VCN-01, an oncolytic adenovirus engineered to degrade the tumor’s stroma and boost immune response, could help overcome barriers that have limited advances in the field. The drug has already been explored in multiple cancer types in over 140 patients across global trials.

Stock Remains in Focus as Clinical Narrative Progresses

As of 10:30 AM, TOVX shares traded at $0.43, reflecting heightened market interest tied to the clinical developments and future milestones. Investors may be watching for additional details from the AACR presentation and upcoming regulatory milestones as the pivotal Phase 3 trial takes shape.

Key Takeaway: Upcoming Data Could Set the Tone for Theriva’s Future

With the promise of new clinical data and the prospect of a pivotal Phase 3 trial on the horizon, Theriva Biologics’ evolving pipeline and ongoing regulatory engagement mark important developments both for the company and for the wider field of pancreatic cancer therapeutics. The upcoming AACR presentation stands out as a milestone for those tracking innovation and investment opportunities in cancer treatment. Investors and oncology watchers alike will be looking for key signals from the presentation and subsequent updates.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI